A randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision (CME) for stage II, III colorectal cancer (CRC): First efficacy results from Japan Clinical Oncology Group Study JCOG0404.

被引：4
|
作者：
Inomata, Masafumi
Katayama, Hiroshi
Mizusawa, Junki
Watanabe, Masahiko
Sugihara, Kenichi
Konishi, Fumio
Yamamoto, Seiichiro
Saito, Shuji
Fujii, Shoichi
Saida, Yoshihisa
Hasegawa, Hirotoshi
Etoh, Tsuyoshi
Moriya, Yoshihiro
Kitano, Seigo
机构：
[1] Oita Univ, Fac Med, Dept Gastroenterol & Pediat Surg, Oita 87011, Japan
[2] Natl Canc Ctr, JCOG Operat Off, Tokyo 104, Japan
[3] Natl Canc Ctr, JCOG Data Ctr, Tokyo 104, Japan
[4] Kitasato Univ, Sch Med, Sagamihara, Kanagawa 228, Japan
[5] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan
[6] Nerima Hikarigtaoka Hosp, Dept Surg, Tokyo, Japan
[7] Natl Canc Ctr, Div Colorectal Surg, Tokyo 104, Japan
[8] Shizuoka Canc Ctr, Dept Colon & Rectal Surg, Shizuoka, Japan
[9] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa 232, Japan
[10] Toho Univ, Ohashi Hosp, Tokyo, Japan
[11] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
[12] Oita Univ, Fac Med, Oita 87011, Japan
[13] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
656
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
    Shin Nishio
    Ryo Kitagawa
    Taro Shibata
    Hiroyuki Yoshikawa
    Ikuo Konishi
    Kimio Ushijima
    Toshiharu Kamura
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 785 - 790
  • [32] Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
    Nishio, Shin
    Kitagawa, Ryo
    Shibata, Taro
    Yoshikawa, Hiroyuki
    Konishi, Ikuo
    Ushijima, Kimio
    Kamura, Toshiharu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 785 - 790
  • [33] Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
    Namikawa, Kenjiro
    Tsutsumida, Arata
    Mizutani, Tomonori
    Shibata, Taro
    Takenouchi, Tatsuya
    Yoshikawa, Shusuke
    Kiyohara, Yoshio
    Uchi, Hiroshi
    Furue, Masutaka
    Ogata, Dai
    Tsuchida, Tetsuya
    Yamazaki, Naoya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (07) : 664 - 667
  • [34] Phase I/II trial of chemoradiotherapy concurrent with S-1 and cisplatin in patients with clinical stage II/III esophageal carcinoma: Results of the Japan Clinical Oncology Group study JCOG 0604.
    Tahara, Makoto
    Fuse, Nozomu
    Mizusawa, Junki
    Sato, Akihiro
    Nihei, Keiji
    Kanato, Keisuke
    Kato, Ken
    Yamazaki, Kentaro
    Muro, Kei
    Takaishi, Hiromasa
    Boku, Narikazu
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102
    Katsumata, N.
    Yoshikawa, H.
    Kobayashi, H.
    Saito, T.
    Kuzuya, K.
    Mizunoe, T.
    Hiura, M.
    Kasamatsu, T.
    Shibata, T.
    Kamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN (TC) VERSUS PACLITAXEL PLUS CISPLATIN (TP) IN STAGE IVB OR RECURRENT CERVICAL CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0505)
    Kitagawa, R.
    Katsumata, N.
    Shibata, T.
    Nakanishi, T.
    Nishimura, S.
    Nishio, S.
    Takano, M.
    Satoh, T.
    Yokota, H.
    Ochiai, K.
    Kigawa, J.
    Kobayashi, H.
    Kanato, K.
    Yoshikawa, H.
    Kamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 126 - 126
  • [37] A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505)
    Kitagawa, Ryo
    Katsumata, Noriyuki
    Shibata, Taro
    Nakanishi, Toru
    Nishimura, Sadako
    Ushijima, Kimio
    Takano, Masashi
    Satoh, Toyomi
    Yoshikawa, Hiroyuki
    Kamura, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)
    Saito, Isamu
    Kitagawa, Ryo
    Fukuda, Haruhiko
    Shibata, Taro
    Katsumata, Noriyuki
    Konishi, Ikuo
    Yoshikawa, Hiroyuki
    Kamura, Toshiharu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 90 - 93
  • [39] A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study)
    Ohue, Masayuki
    Iwasa, Satoru
    Kanemitsu, Yukihide
    Hamaguchi, Tetsuya
    Shiozawa, Manabu
    Ito, Masaaki
    Yasui, Masayoshi
    Katayama, Hiroshi
    Mizusawa, Junki
    Shimada, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (01) : 84 - 87
  • [40] Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)
    Morizane, Chigusa
    Okusaka, Takuji
    Mizusawa, Junki
    Takashima, Atsuo
    Ueno, Makoto
    Ikeda, Masafumi
    Hamamoto, Yasuo
    Ishii, Hiroshi
    Boku, Narikazu
    Furuse, Junji
    CANCER SCIENCE, 2013, 104 (09): : 1211 - 1216
12345